ACR Journals On Air
The SLEek Study
Oct 15, 2024
Joan T. Merrill, a leading figure in lupus research at the Oklahoma Medical Research Foundation, shares insights on her groundbreaking SLEek Study. She discusses the efficacy and safety of upadacitinib and elsubrutinib for systemic lupus erythematosus. The conversation delves into innovative trial designs, challenges in lupus treatment trials during the pandemic, and personal anecdotes from her unique journey into rheumatology. Merrill emphasizes how patient experiences shape research and highlights the promising outcomes of recent clinical trials.
42:40
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The SLEek Study demonstrated that combining U-Petacitinib and elsubrutinib potentially enhances treatment efficacy and reduces corticosteroid use in lupus patients.
- Rigorous patient selection and ongoing safety monitoring were crucial for ensuring reliable outcomes and managing risks during the trial execution.
Deep dives
Overview of the Lupus Trial
A recent Phase II randomized controlled trial focused on the efficacy and safety of U-Petacitinib and L-Subrutinib, either alone or in combination, for patients with systemic lupus erythematosus. This study emerged from a need for more effective treatments for lupus, as challenges in trial design have historically led to disappointing results. The trial also showcased the use of ABBV599, a unique combination of the two agents, which is believed to potentially enhance treatment efficacy while addressing concerns about toxicities. The innovative approach of investigating drug combinations aims to improve trial efficiency and broaden understanding of pharmacokinetics in lupus treatment.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
